Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study

J. Panes,A. Dignass,G. Lichtenstein, K. H. Huang,M. Germinaro, N. Houck, C. Han,Y. Miao,H. Zhang, N. Abu Farsakh, B. Patel, D. Owczarek,T. Hisamatsu,B. Sands,B. Bressler

JOURNAL OF CROHNS & COLITIS(2024)

引用 0|浏览17
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要